EP4179099A1 - Procédé de production d'acide guanidinoacétique par fermentation - Google Patents

Procédé de production d'acide guanidinoacétique par fermentation

Info

Publication number
EP4179099A1
EP4179099A1 EP21734021.5A EP21734021A EP4179099A1 EP 4179099 A1 EP4179099 A1 EP 4179099A1 EP 21734021 A EP21734021 A EP 21734021A EP 4179099 A1 EP4179099 A1 EP 4179099A1
Authority
EP
European Patent Office
Prior art keywords
microorganism
arginine
gene
activity
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21734021.5A
Other languages
German (de)
English (en)
Inventor
Frank Schneider
Frank JANKOWITSCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations GmbH filed Critical Evonik Operations GmbH
Publication of EP4179099A1 publication Critical patent/EP4179099A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1022—Transferases (2.) transferring aldehyde or ketonic groups (2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01002—Guanidinoacetate N-methyltransferase (2.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/03—Acyl groups converted into alkyl on transfer (2.3.3)
    • C12Y203/03009—Malate synthase (2.3.3.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01002—Alanine transaminase (2.6.1.2), i.e. alanine-aminotransferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01004—Glycine transaminase (2.6.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01044—Alanine--glyoxylate transaminase (2.6.1.44)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/04—Amidinotransferases (2.1.4)
    • C12Y201/04001—Glycine amidinotransferase (2.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)

Definitions

  • the present invention relates to a microorganism transformed to be capable of producing guanidinoacetic acid (GAA) and to a method for the fermentative production of GAA using such microorganism.
  • GAA is an organic compound used as animal feed additive (US2011257075 A1).
  • GAA is a natural precursor of creatine (e.g. Humm et al., Biochem. J. (1997) 322, 771-776). Therefore, the supplementation of GAA allows for an optimal supply of creatine in the organism.
  • the present invention pertains to a method to produce GAA by a fermentative process using industrial feed stocks (e.g. ammonia, ammonium salts and glucose or sugar containing substrates) as starting material.
  • industrial feed stocks e.g. ammonia, ammonium salts and glucose or sugar containing substrates
  • GAA and L-ornithine are formed from arginine and glycine as starting materials by the catalytic action of an L-arginine:glycine-amidinotransferase (AGAT; EC 2.1.4.1), which is the first step in creatine biosynthesis:
  • L-arginine + glycine AGAT > L-ornithine + GAA Guthmiller et al. J Biol Chem. 1994 Jul 1 ;269(26):17556-60 have characterized a rat kidney AGAT by cloning and heterologously expressing the enzyme in Escherichia coli (E. coli ).
  • Muenchhoff et al. FEBS Journal 277 (2010) 3844-3860 report the first characterization of an AGAT from a prokaryote also by cloning and heterologously expressing the enzyme in E. coli. Sosio et al.
  • Fan Wenchao discloses a method for the production of creatine by fermentation of non-pathogenic microorganisms, such as C. glutamicum (CN106065411 A).
  • the microorganism has the following biotransformation functions: glucose conversion to L-glutamic acid; conversion of L-glutamic acid to N-acetyl-L-glutamic acid; conversion of N-acetyl-L-glutamic acid to N-acetyl-L-glutamic acid semialdehyde; conversion of N-acetyl-L-glutamic acid semialdehyde to N- acetyl-L-ornithine; conversion of N-acetyl-L-ornithine to L-ornithine; conversion of L-ornithine to L-citrulline; conversion of L-citrulline to arginino-succinic acid; conversion of arginino-succinic acid to L-arginine; conversion of L-arg
  • the microorganism overexpresses one or more enzymes selected from the group consisting of N-acetylglutamate-synthase, N-acetylornithine-d- aminotransferase, N-acetylornithinase, ornithine-carbamoyl transferase, argininosuccinate synthetase, glycine amidino-transferase (EC: 2.1. 4.1), and guanidinoacetate N-methyltransferase (EC: 2.1.1.2).
  • the microorganism overexpresses preferably glycine amidinotransferase (L- arginine:glycine amidinotransferase) and guanidinoacetate N-methyltransferase.
  • the so called glyoxylate shunt pathway naturally occurring in microorganisms, such as E. coli or C. glutamicum, is a side reaction of the tri-carbonic acid (TCA) cycle (Krebs cycle) and includes the formation of glyoxylate and succinate from isocitrate by isocitrate lyase and the formation of malate from glyoxylate and acetyl-CoA by malate synthase (Salusjarvi et al., Applied Microbiology and Biotechnology (2019) 103:2525-2535).
  • TCA tri-carbonic acid
  • glyoxylate amino transferases are known and vary in their substrate specificity with respect to the amino donor (cf. e.g. Kameya et al. FEBS Journal 277 (2010) 1876-1885; Liepman and Olsen, Plant Physiol. Vol. 131 , 2003, 215-227; Sakuraba et al., JOURNAL OF BACTERIOLOGY, Aug. 2004, p. 5513-5518; Takada and Noguchi, Biochem. J. (1985) 231 , 157-163). Since most of these glyoxylate aminotransferase are able to use different amino acids as amino donors, they are often annotated with different EC numbers. However, all these aminotransferases have in common that they use glyoxylate as acceptor molecule, or, in case of the reverse reaction, glycine as donor molecule.
  • Methionine glyoxylate transaminase (EC 2.6.1.73) catalyzes the reaction:
  • Kynurenine:glyoxylate transaminase (EC 2.6.1.63) catalyzes the reaction: kynurenine + glyoxylate ⁇ > 4-(2-aminophenyl)-2,4-diketo-butanoate + glycine.
  • S)-Ureido-glycine glyoxylate transaminase (EC 2.6.1.112) catalyzes the reaction:
  • the activity activity of a protein having the function of a malate synthase may be decreased by mutating the protein to a protein having less enzymic activity than the wildtype protein, by attenuating the expression of a gene encoding the enzyme having the function of a malate synthase compared to the expression of the respective gene in the wildtype microorganism, by decreasing the efficiency of translation, e.g. by changing an ATG start codon to GTG, by introducing secondary structures into the 5’ untranslated region of the mRNA or by attenuating the codon usage or by deleting the gene encoding the enzyme having the function of a malate synthase.
  • the microorganism of the present invention further comprises an increased activity of an enzyme having the function of a glyoxylate aminotransferase compared to the respective enzymic activity in the wildtype microorganism.
  • the microorganism according to the present invention comprises preferably at least one gene encoding a protein having the enzymic activity of a glyoxylate aminotransferase.
  • At least one gene encoding a protein having the enzymic activity of a glyoxylate aminotransferase is overexpressed.
  • the microorganism of the present invention microorganism has an increased ability to produce L-arginine compared with the ability of the wildtype microorganism.
  • a microorganism having an increased ability to produce L- arginine means a microorganism producing L-arginine in excess of its own need.
  • L-arginine producing microorganisms are e.g. C. glutamicum ATCC 21831 or those disclosed by Park et al. (NATURE COMMUNICATIONS
  • the microorganism has increased activities of an enzyme having the function of a carbamoylphosphate synthase (EC 6.3.4.16) compared to the respective enzymic activity in the wildtype microorganism.
  • the activity of an enzyme having the function of an argininosuccinate lyase (E.C. 4.3.2.1) in the microorganism according to the present invention may be increased compared to the respective enzymic activity in the wildtype microorganism.
  • the activity of an enzyme having the function of an argininosuccinate synthetase may be also increased compared to the respective enzymic activity in the wildtype microorganism.
  • Increased enzyme activities in microorganisms can be achieved, for example, by mutation of the corresponding endogenous gene.
  • a further measure to increase enzymic activities may be to stabilize the mRNA coding for the enzymes.
  • the increased activities of the above-mentioned enzymes may also be achieved by overexpressing the genes coding for the respective enzymes.
  • the microorganism according to the present invention preferably also comprises at least one or more overexpressed genes selected from the group consisting of a gene (e.g. argF/argF2/argl) coding for a protein having the function of an ornithine carbamoyltransferase (EC 2.1.3.3), a gene (e.g. argG) coding for a protein having the function of an argininosuccinate synthetase (E.C.
  • a gene e.g. argF/argF2/argl
  • a gene e.g. argG coding for a protein having the function of an argininosuccinate synthetase (E.C.
  • argH argininosuccinate lyase
  • arginine operon (argCJBDFR) may be overexpressed.
  • the argR gene coding for the arginine responsive repressor protein ArgR may be attenuated or deleted.
  • Overexpression of a gene is generally achieved by increasing the copy number of the gene and/or by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding site and/or by codon usage optimization of the start codon or of the whole gene or a combination comprising a selection of or all methods mentioned above.
  • the gene coding for a protein having the function of an L-arginine:glycine amidinotransferase is heterologous.
  • a heterologous protein means a protein that is not naturally occurring in the microorganism.
  • a homologous or endogenous gene means that the gene including its function as such or the nucleotide sequence of the gene is naturally occurring in the microorganism or is “native” in the microorganism.
  • Enzymes or proteins with an L-arginie:glycine- amidinotransferase (AGAT) activity are also described to possess a conserved domain that belongs to the PFAM Family: Amidinotransf (PF02274) (: Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.”, Nucleic Acids Res.
  • the gene coding for a protein having the function of an L-arginine:glycine amidinotransferase may further be overexpressed.
  • Overexpression of a gene is generally achieved by increasing the copy number of the gene and/or by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding site and/or by codon usage optimization of the start codon or of the whole gene or a combination comprising a selection or all methods mentioned above.
  • the protein having the function of an L-arginine:glycine amidinotransferase in the microorganism of the present invention may comprise an amino acid sequence which is at least 80 % homologous, preferably at least 90 % homologous to the amino acid sequence according to SEQ ID NO: 11.
  • the amino acid sequence of the L-arginine:glycine amidinotransferase is identical to amino acid sequence according to SEQ ID NO: 11.
  • the protein having the enzymic activity of a glyoxylate aminotransferase in the microorganism according to the present invention comprises an amino acid sequence which is at least 80 % homologous to the amino acid sequence according to SEQ ID NO: 2, according to SEQ ID NO: 5 or according to SEQ ID NO: 8.
  • the microorganism of the present invention may belong to the genus Corynebacterium, preferably Corynebacterium glutamicum (C. glutamicum), or to the genus Enterobacteriaceae, preferably Escherichia coli (E. coii), or to the genus Pseudomonas, preferably Pseudomonas putida (P. putida).
  • C. glutamicum Corynebacterium glutamicum
  • E. coii Escherichia coli
  • Pseudomonas preferably Pseudomonas putida (P. putida).
  • An increased enzymic activity of a protein in a microorganism, in particular in the microorganism of the present invention compared to the respective activity in the wildtype microorganism can be achieved for example by a mutation of the protein, in particular by a mutation conferring the protein a feedback resistance e.g. against a product of an enzyme-catalyzed reaction, or by increased expression of a gene encoding the protein having the enzymic activity compared to the expression of the respective gene in the wildtype microorganism.
  • Increased expression or overexpression of a gene in a microorganism, in particular in the microorganism of the present invention compared to the respective activity in the wildtype microorganism can be achieved by increasing the copy number of the gene and/or by an enhancement of regulatory factors, e.g. by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding site and/or by codon usage optimization of the start codon or of the whole gene.
  • the enhancement of such regulatory factors which positively influence gene expression can, for example, be achieved by modifying the promoter sequence upstream of the structural gene in order to increase the effectiveness of the promoter or by completely replacing said promoter with a more effective or a so-called strong promoter. Promoters are located upstream of the gene.
  • a promoter is a DNA sequence consisting of about 40 to 50 base pairs and which constitutes the binding site for an RNA polymerase holoenzyme and the transcriptional start point, whereby the strength of expression of the controlled polynucleotide or gene can be influenced.
  • strong promoters for example by replacing the original promoter with strong, native (originally assigned to other genes) promoters or by modifying certain regions of a given, native promoter (for example its so-called -10 and -35 regions) towards a consensus sequence, e.g. as taught by M. Patek et al. (Microbial Biotechnology 6 (2013), 103-117) for C. glutamicum.
  • a “strong” promoter is the superoxide dismutase ( sod) promoter (“Psod”; Z. Wang et al., Eng. Life Sci. 2015, 15, 73-82).
  • a “functional linkage” is understood to mean the sequential arrangement of a promoter with a gene, which leads to a transcription of the gene.
  • the genetic code is degenerated which means that a certain amino acid may be encoded by a number of different triplets.
  • codon usage refers to the observation that a certain organism will typically not use every possible codon for a certain amino acid with the same frequency.
  • an organism will typically show certain preferences for specific codons meaning that these codons are found more frequently in the coding sequence of transcribed genes of an organism. If a certain gene foreign to its future host, i.e. from a different species, should be expressed in the future host organism the coding sequence of said gene should then be adjusted to the codon usage of said future host organism (i.e. codon usage optimization).
  • the method of the present invention may further comprise the step of isolating GAA from the fermentation broth.
  • the gene coding for an enzyme having the activity of a guanidinoacetate N- methyltransferase is overexpressed.
  • the present invention also concerns a method for the fermentative production of creatine, comprising the steps of a) cultivating the microorganism according to the present invention comprising a gene coding for an enzyme having the activity of a guanidinoacetate N- methyltransferase in a suitable medium under suitable conditions, and b) accumulating creatine in the medium to form a creatine containing fermentation broth.
  • the method further comprises isolating creatine from the creatine containing fermentation broth creatine may be be extracted from fermentation broth by isoelectric point method and / or ion exchange method. Alternatively, creatine can be further purified by a method of recrystallization in water.
  • Plasmid DNA was isolated from E. coli cells using the QIAprep Spin Miniprep Kit from Qiagen (Hilden, Germany, Cat. No. 27106) according to the instructions of the manufacturer.
  • PCR Polymerase chain reaction
  • PCR Polymerase chain reaction
  • Non-proof-reading polymerase Kits were used for determining the presence or absence of a desired DNA fragment directly from E. coli or C. glutamicum colonies.
  • the Phusion® High-Fidelity DNA Polymerase Kit (Phusion Kit) from New England BioLabs Inc. (Ipswich, USA, Cat. No. M0530) was used for template-correct amplification of selected DNA regions according to the instructions of the manufacturer (see Table 2).
  • Table 2 Thermocycling conditions for PCR with Phusion® High-Fidelity DNA Polymerase Kit from New England BioLabs Inc. b. Taq PCR Core Kit (Taq Kit) from Qiagen (Hilden, Germany, Cat. No.201203) was used to amplify a desired segment of DNA in order to confirm its presence. The kit was used according to the instructions of the manufacturer (see Table 3).
  • Table 3 Thermocycling conditions for PCR with Taq PCR Core Kit (Taq Kit) from Qiagen.
  • Table 4 Thermocycling conditions for PCR with SapphireAmp® Fast PCR Master Mix (Sapphire Mix) from Takara Bio Inc. d.
  • oligonucleotide primers were synthesized by Eurofins Genomics GmbH (Ebersberg, Germany) using the phosphoramidite method described by McBride and Caruthers (1983).
  • PCR template either a suitably diluted solution of isolated plasmid DNA or of total DNA isolated from a liquid culture or the total DNA contained in a bacterial colony (colony PCR) was used.
  • colony PCR the template was prepared by taking cell material with a toothpick from a colony on an agar plate and placing the cell material directly into the PCR reaction tube. The cell material was heated for 10 sec.
  • PCR amplificates and restriction fragments were cleaned up using the QIAquick PCR Purification Kit from Qiagen (Hilden, Germany; Cat. No. 28106), according to the manufacturer’s instructions. DNA was eluted with 30 pi 10 mM Tris*HCI (pH 8.5). Determining DNA concentration
  • DNA concentration was measured using the NanoDrop Spectrophotometer ND-1000 from PEQLAB Biotechnologie GmbH, since 2015 VWR brand (Er Weg, Germany). Assembly cloning
  • Transformation of C. glutamicum with plasmid-DNA was conducted via electroporation using a plausibleGene PulserXcell" (Bio-Rad Laboratories GmbH, Feldmün, Germany) as described by Ruan et al. (2015). Electroporation was performed in 1 mm electroporation cuvettes (Bio-Rad Laboratories GmbH, Feldmün, Germany) at 1 .8 kV and a fixed time constant set to 5 ms. Transformed cells were selected on BHI-agar containing 134 g/l sorbitol, 2.5 g/l Yeast Extract and 25 mg/I kanamycin. Determining nucleotide sequences
  • the main cultures were started by inoculating the 2.4 ml production medium (PM) containing wells of the 24 Well WDS-Plate with each 100 pi of the resuspended cells from the precultures.
  • the composition of the production medium (PM) is shown in Table 6.
  • the main cultures were incubated for 72 h at 30 °C and 300 rpm in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) until complete consumption of glucose.
  • the glucose concentration in the suspension was analysed with the blood glucose-meter OneTouch Vita® from LifeScan (Johnson & Johnson Medical GmbH, Neuss, Germany).
  • yeast extract FM902 (Angel Yeast Co., LTD, Hubei, P.R. China) contains various peptides and amino acids, its content of L-arginine and glycine was measured as follows.
  • the samples were prepared by dissolving 1 g of yeast extract in 20 ml of water. The solution was filled up with water to a total volume of 25 ml, mixed thoroughly and filtered using a 0.2 pM nylon syringe filter.
  • the samples were prepared by dissolving 1 g yeast extract in 10 ml 6M HCI and incubating them for 24h at 110°C. Then, water was added up to a total volume of 25 ml. The solution was mixed thoroughly and filtered using a 0.2 pM nylon syringe filter.
  • buffer A an aqueous solution containing in 20 I 263 g trisodium citrate, 120 g citric acid, 1100 ml methanol, 100 ml 37 % HCI and 2 ml octanoic acid (final pH 3.5) was used.
  • buffer B an aqueous solution containing in 20 I 392 g trisodium citrate, 100 g boric acid and 2 ml octanoic acid (final pH 10.2) was used.
  • the free amino acids were coloured with ninhydrin through post-column derivatization and detected photometrically at 570 nm.
  • Table 7 shows the content of free and total L-arginine and glycine determined in yeast extract FM902 (Angel Yeast Co., LTD, Hubei, P.R. China), as well as the resulting amounts in the production medium (PM).
  • Table 7 Content of L-arginine and glycine in yeast extract (YE) FM902 and resulting concentrations in production medium (PM) containing 1.5 g/l YE.
  • GGT1 of Arabidopsis thaliana (Genbank accession Number NM_102180, SEQ ID NO:1) codes for a glutamate:glyoxylate aminotransferase (Genbank accession Number NP_564192, SEQ ID NO:2).
  • the amino acid sequence of the GGT1 protein was translated back into a DNA sequence optimized for the codon usage of C. glutamicum.
  • a Shine-Dalgarno-Sequenz was added directly upstream of the open reading frame (AGGAAAGGAGAGGATTG; Shi, 2018) and the ends of the resulting sequence were expanded with motifs for subsequent subcloning.
  • Example 2 Cloning of the gene GGT2 coding fora glyoxylate aminotransferase from Arabidopsis thaliana
  • the gene AOAT2 (synonym: GGT2) of Arabidopsis thaliana (Genbank accession Number NM_001036185, SEQ ID NO:4) codes for alanine-2-oxoglutarate aminotransferase 2 (Genbank accession Number NP_001031262, SEQ ID NO:5).
  • the amino acid sequence of the GGT2 protein was translated back into a DNA sequence optimized for the codon usage of C. glutamicum.
  • a Shine-Dalgarno-Sequenz was added directly upstream of the open reading frame (AGGAAAGGAGAGGATTG; Shi, 2018) and the ends of the resulting sequence were expanded with motifs for subsequent subcloning.
  • AtGGT2_opt_RBS The resulting DNA sequence AtGGT2_opt_RBS (SEQ ID NO:6) was ordered for gene synthesis from Eurofins Genomics GmbH (Ebersberg, Germany) and it was delivered as part of a cloning plasmid conferring resistance to ampicillin (designated as pEX-A258-AtGGT2_opt_RBS).
  • Plasmid pEC-XK99E_AGAT_Mp was digested using the restriction endonuclease BamHI and terminal phosphates were removed using theticianFastAP Thermosensitive Alkaline Phosphatase" (Thermo Fisher Scientific, Waltham, USA). The digested DNA was then purified using theticianQIAquick Gel Extraction Kit” (Qiagen GmbH, Hilden, Germany).
  • a toothpick was used to remove cell material from the colony and to transfer it onto BHI agar containing 25 mg/I kanamycin and onto BHI agar containing 10 % saccharose.
  • the agar plates were incubated for 60 h at 33°C.
  • Clones that proved to be sensitive to kanamycin and resistant to saccharose were examined by PCR and DNA sequencing for the appropriate integration of the sod promoter.
  • the resulting strain was named ATCC13032_Psod-carAB.
  • Example 8 Chromosomal deletion of the gene aceB (NCgl2247) in C. glutamicum ATCC13032.
  • the plasmid pK18mobsacB_DaceB was constructed as follows. Plasmid pK18mobsacB (Schafer, 1994) was cut using Xbal and the linearized vector DNA (5721 bps) was purified using theticianQIAquick Gel Extraction Kit“ (Qiagen GmbH, Hilden, Germany).
  • the linearized plasmid and the PCR products were then assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520).
  • the resulting deletion vector was named pK18mobsacB_DaceB. It was verified by restriction enzyme digestion and DNA sequencing.
  • Example 9 Chromosomal deletion of the gene aceB (NCgl2247) in C. glutamicum ATCC13032_Psod-carAB.
  • strains ATCC13032/pEC-XK99E, ATCC13032/pEC-XK99E_AGAT_Mp, and ATCC13032_DaceB/pEC-XK99E_AGAT_Mp were cultivated in the Wouter Duetz system, and the resulting GAA titers were determined.
  • the production medium (PM) contained 40 g/l D-glucose and 1.90 g/L L-arginine, but no additional glycine.
  • Table 11 Impact of reduced activity of malate synthase on GAA production in the presence of 1.90 g/L L-arginine.
  • Strain ATCC13032/pEC-XK99E_AGAT_Mp having a polynucleotide coding for the AGAT from Moorea producens, produced 122 mg/L of GAA.
  • Strain ATCC13032_DaceB/pEC-XK99E_AGAT_Mp having a polynucleotide coding for the AGAT from Moorea producens, and a deleted aceB gene, produced 155 mg/L of GAA.
  • ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AtGGT1 also have a polynucleotide coding for the AGAT from Moorea producens and a deleted aceB gene.
  • each strain has a polynucleotide coding for a glyoxylate aminotransferase. These strains produced 236 mg/I, 242 mg/I, and 180 mg/I of GAA respectively.
  • Example 13 Impact of reduced activity of malate synthase combined with increased ability to produce L-arginine on GAA production.
  • the production medium (PM) contained 40 g/l D- glucose and 1.90 g/L L-arginine, but no additional glycine.
  • Table 13 Impact of reduced activity of malate synthase and increased ability to produce L-arginine on GAA production in the presence of 1 .90 g/L L-arginine.
  • strain ATCC13032_DaceB/pEC-XK99E_AGAT_Mp having a polynucleotide coding for the AGAT from Moorea producens and a deleted aceB gene, produced 155 mg/L of GAA.
  • Strain ATCC13032_Psod-carAB_DaceB/pEC-XK99E_AGAT_Mp also has a polynucleotide coding for the AGAT from Moorea producens and a deleted aceB gene. In addition, it has an increased ability to produce L-arginine. This strain produced 243 mg/I of GAA.
  • Example 14 Combined impact of reduced malate synthase activity, increased glyoxylate aminotransferase activity, and increased ability to produce L-arginine on GAA production.
  • strains ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AtGGT 1 ATCC13032_DaceB/pEC- XK99E_AGAT_Mp_AtGGT 1 , ATCC13032_DaceB/pEC- XK99E_AGAT_Mp_AtGGT2, ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AGT_TI,
  • ATCC13032_Psod-carAB_DaceB/pEC-XK99E_AGAT_Mp_AtGGT1 ATCC13032_Psod- carAB_DaceB/pEC-XK99E_AGAT_Mp_AtGGT2
  • ATCC13032_Psod-carAB_DaceB/pEC- XK99E_AGAT_Mp_AGT_TI were cultivated in the Wouter Duetz system, and the resulting GAA titers were determined. Due to the insertion of the strong sod-promoter upstream of the cromosomal genes carA and carB, the latter three strains have an improved the ability to produce L-arginine.
  • the production medium (PM) contained 40 g/l D-glucose and 1.90 g/L L-arginine, but no additional glycine.
  • Table 14 Combined impact of reduced malate synthase activity, increased glyoxylate aminotransferase activity, and increased ability to produce L-arginine on GAA production in the presence of 1.90 g/L L-arginine.
  • strains ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AtGGT1 strains ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AtGGT1 .
  • ATCC13032_DaceB/pEC-XK99E_AGAT_Mp_AtGGT2 having a polynucleotide coding for the AGAT from Moorea producens, a deleted aceB gene, and a polynucleotide coding for a glyoxylate aminotransferase, produced 236 mg/I, 242 mg/I, and 180 mg/I of GAA respectively.
  • ATCC13032_Psod-carAB_DaceB/pEC-XK99E_AGAT_Mp_AtGGT1 ATCC13032_Psod- carAB_DaceB/pEC-XK99E_AGAT_Mp_AtGGT2
  • ATCC13032_Psod-carAB_DaceB/pEC- XK99E_AGAT_Mp_AGT_TI also have a polynucleotide coding for the AGAT from Moorea producens, a deleted aceB gene, and a polynucleotide coding for a glyoxylate aminotransferase. In addition, they have an increased ability to produce L-arginine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un micro-organisme transformé avec de la L-arginine:glycine amidotransférase et une malate synthase réduite et une glyoxylate aminotransférase pour pouvoir produire de l'acide guanidinoacétique (AGA) et un procédé de production d'AGA par fermentation à l'aide d'un tel micro-organisme. La présente invention concerne également un procédé de production de créatine par fermentation.
EP21734021.5A 2020-07-09 2021-06-28 Procédé de production d'acide guanidinoacétique par fermentation Pending EP4179099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184966 2020-07-09
PCT/EP2021/067647 WO2022008276A1 (fr) 2020-07-09 2021-06-28 Procédé de production d'acide guanidinoacétique par fermentation

Publications (1)

Publication Number Publication Date
EP4179099A1 true EP4179099A1 (fr) 2023-05-17

Family

ID=71575016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21734021.5A Pending EP4179099A1 (fr) 2020-07-09 2021-06-28 Procédé de production d'acide guanidinoacétique par fermentation

Country Status (15)

Country Link
US (1) US11999982B2 (fr)
EP (1) EP4179099A1 (fr)
JP (1) JP7759930B2 (fr)
KR (1) KR20230035564A (fr)
CN (1) CN116096908A (fr)
AR (1) AR122886A1 (fr)
AU (1) AU2021303704A1 (fr)
BR (1) BR112023000183A2 (fr)
IL (1) IL299713A (fr)
MX (1) MX2023000344A (fr)
MY (1) MY207800A (fr)
PH (1) PH12023550035A1 (fr)
TW (1) TW202217005A (fr)
WO (1) WO2022008276A1 (fr)
ZA (1) ZA202301312B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115803442A (zh) 2020-07-09 2023-03-14 赢创运营有限公司 发酵制备胍基乙酸的方法
IL299713A (en) 2020-07-09 2023-03-01 Evonik Operations Gmbh A method for the fermentation production of guanidinoacetic acid
CN119325504A (zh) 2022-06-03 2025-01-17 赢创运营有限公司 通过使用nadh依赖性脱氢酶生产胍基乙酸(gaa)的改良的生物技术方法
EP4532739A1 (fr) 2022-06-03 2025-04-09 Evonik Operations GmbH Procédé de production d'acide guanidino acétique (gaa)
CN120129742A (zh) * 2022-11-03 2025-06-10 赢创运营有限公司 通过靶向引入或增加属于氨基酸-多胺-有机阳离子超家族的跨膜转运蛋白的活性来产生胍基乙酸(gaa)的改进的生物技术工艺
EP4612280A1 (fr) 2022-11-03 2025-09-10 Evonik Operations GmbH Procédé biotechnologique amélioré pour produire de l'acide guanidinoacétique (gaa) par introduction ciblée ou par augmentation de l'activité d'une protéine exportateur transmembranaire
WO2024160790A1 (fr) 2023-02-01 2024-08-08 Evonik Operations Gmbh Procédé de production par fermentation d'acide guanidinoacétique à l'aide d'un micro-organisme comprenant un gène hétérologue de l-thréonine aldolase
JP2026503156A (ja) * 2023-02-01 2026-01-27 エボニック オペレーションズ ゲーエムベーハー 異種Ｌ－トレオニン３－デヒドロゲナーゼ遺伝子（ｔｄｈ）とグリシンＣ－アセチルトランスフェラーゼ遺伝子（ｋｂｌ）とを含む微生物を使用したグアニジノ酢酸の発酵生産のための方法
KR20250025214A (ko) 2023-08-14 2025-02-21 한국수력원자력 주식회사 당뇨병의 발생을 예측하는 방법
KR102940709B1 (ko) 2023-08-14 2026-03-17 한국수력원자력 주식회사 당뇨병의 예방을 위한 방안의 제공 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110904018A (zh) * 2018-09-14 2020-03-24 中国科学院天津工业生物技术研究所 5-氨基乙酰丙酸生产菌株及其构建方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849250A (en) 1971-02-26 1974-11-19 Kyowa Hakko Kogyo Kk Process for producing l-arginine by fermentation
US7160705B2 (en) 2000-04-28 2007-01-09 Ajinomoto Co., Inc. Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine
AU2003254814B2 (en) * 2002-08-09 2010-04-01 Ajinomoto Co., Inc. Method of elevating GGT activity of plant, plant with elevated GGT activity and method of constructing the same
BRPI0511842B1 (pt) 2004-06-09 2014-08-12 Alzchem Trostberg Gmbh Uso de ácido guanidino acético como aditivo para ração animal
KR101835935B1 (ko) 2014-10-13 2018-03-12 씨제이제일제당 (주) L-아르기닌을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아르기닌의 제조 방법
CN106065411B (zh) 2016-08-10 2021-12-07 洛阳华荣生物技术有限公司 发酵法生产肌酸
JP2019531759A (ja) 2016-10-26 2019-11-07 味の素株式会社 目的物質の製造方法
US11555209B2 (en) * 2017-12-19 2023-01-17 Lanzatech, Inc. Microorganisms and methods for the biological production of ethylene glycol
KR102269637B1 (ko) * 2018-12-26 2021-06-28 대상 주식회사 L-시트룰린 또는 l-아르기닌 생산능이 향상된 변이 균주 및 이를 이용한 l-시트룰린 또는 l-아르기닌의 제조 방법
JP7594536B2 (ja) 2019-02-15 2024-12-04 ブラスケム エス．エー． 逆グリオキシル酸短絡を通じたグリコール酸およびグリシンの生成のための微生物および方法
CN111748506B (zh) 2019-03-29 2022-07-05 中国科学院微生物研究所 产胍基乙酸的工程菌及其构建方法与应用
CN115803442A (zh) 2020-07-09 2023-03-14 赢创运营有限公司 发酵制备胍基乙酸的方法
IL299713A (en) 2020-07-09 2023-03-01 Evonik Operations Gmbh A method for the fermentation production of guanidinoacetic acid
US20250277226A1 (en) 2021-05-21 2025-09-04 Evonik Operations Gmbh Improved biotechnological method for producing guanidino acetic acid (gaa) by inactivation of an amino acid exporter

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110904018A (zh) * 2018-09-14 2020-03-24 中国科学院天津工业生物技术研究所 5-氨基乙酰丙酸生产菌株及其构建方法和应用

Also Published As

Publication number Publication date
WO2022008276A1 (fr) 2022-01-13
JP7759930B2 (ja) 2025-10-24
PH12023550035A1 (en) 2024-03-11
US11999982B2 (en) 2024-06-04
IL299713A (en) 2023-03-01
ZA202301312B (en) 2023-10-25
US20230265471A1 (en) 2023-08-24
BR112023000183A2 (pt) 2023-01-31
CN116096908A (zh) 2023-05-09
MX2023000344A (es) 2023-02-13
AU2021303704A1 (en) 2023-03-09
KR20230035564A (ko) 2023-03-14
AR122886A1 (es) 2022-10-12
JP2023532782A (ja) 2023-07-31
MY207800A (en) 2025-03-20
TW202217005A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
AU2020410242B2 (en) Method for the fermentative production of guanidinoacetic acid
US11999982B2 (en) Method for the fermentative production of guanidinoacetic acid
US12065677B2 (en) Method for the fermentative production of guanidinoacetic acid
WO2022243116A1 (fr) Procédé biotechnologique amélioré de production d'acide guanidino-acétique (gaa) par inactivation d'un agent d'exportation d'acides aminés
AU2023281826B2 (en) Improved biotechnological method for producing guanidino acetic acid (gaa) by using nadh-dependent dehydrogenases
US12312622B2 (en) Method for producing guanidino acetic acid (GAA)
EP4612281A1 (fr) Procédé biotechnologique amélioré pour produire de l'acide guanidinoacétique (gaa) par l'introduction ciblée ou l'augmentation de l'activité d'une protéine de transport transmembranaire appartenant à la superfamille des acides aminés-polyamines-organocations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221230

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240219